



ND

# Medical Policies



Policy Number:	X-5125		
Policy Name:	Minimally Invasive Approaches to Vertebral Fractures and Osteolytic Lesions of the Spine		
Policy Type:	Medical	Policy Subtype:	Radiology
Effective Date:	11-03-2025	Review Date:	09-01-2026
Last Review Date:	09-04-2025		

## Description

Percutaneous vertebroplasty, percutaneous balloon kyphoplasty, radiofrequency kyphoplasty, and mechanical vertebral augmentation are interventional techniques involving the fluoroscopically guided injection of polymethyl methacrylate into a weakened vertebral body or a cavity created in the vertebral body with a balloon or mechanical device. The techniques have been investigated to provide mechanical support and symptomatic relief in patients with osteoporotic vertebral compression fractures or those with osteolytic lesions of the spine (eg, multiple myeloma, metastatic malignancies); as a treatment for sacral insufficiency fractures; and as a technique to limit blood loss related to surgery.

## Policy Application

All claims submitted under this policy's section will be processed according to the policy effective date and associated revision effective dates in effect on the date of service

## Policy

Coverage is subject to the specific terms of the member's benefit plan

## Percutaneous Vertebroplasty and Sacroplasty

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (eg, analgesics, physical therapy, rest) for at least 6 weeks.

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that are less than 6 weeks in duration that have led to hospitalization or persist at a level that prevents ambulation.

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

Percutaneous vertebroplasty is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

Percutaneous sacroplasty is considered **investigational** for all indications, including use in sacral insufficiency fractures due to osteoporosis and sacral lesions due to multiple myeloma or metastatic malignancies.

Procedure Codes

22510	22511	22512	0200T	0201T
-------	-------	-------	-------	-------

Percutaneous Balloon Kyphoplasty, Radiofrequency Kyphoplasty, and Mechanical Vertebral Augmentation

Balloon kyphoplasty may be considered **medically necessary** for the treatment of symptomatic thoracolumbar osteoporotic vertebral compression fractures that have failed to respond to conservative treatment (eg, analgesics, physical therapy, rest) for at least 6 weeks.

Mechanical vertebral augmentation with a Food and Drug Administration (FDA)-cleared device may be considered **medically necessary** for the treatment of symptomatic thoracolumbar osteoporotic vertebral compression fractures that have failed to respond to conservative treatment (eg, analgesics, physical therapy, rest) for at least 6 weeks.

Balloon kyphoplasty may be considered **medically necessary** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

Mechanical vertebral augmentation with an FDA-cleared device may be considered **medically necessary** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

Balloon kyphoplasty or mechanical vertebral augmentation with an FDA-cleared device is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

Radiofrequency kyphoplasty is considered **investigational**.

Mechanical vertebral augmentation using any other device is considered **investigational**.

Procedure Codes

22513	22514	22515
-------	-------	-------

Summary of Evidence

For individuals who have symptomatic osteoporotic vertebral fractures between 6 weeks and 1 year old who receive vertebroplasty, the evidence includes 2 randomized sham-controlled trials, nonblinded randomized controlled trials (RCTs) comparing vertebroplasty with conservative management, and several meta-analyses. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Despite the completion of multiple RCTs, including 2 with sham controls, the efficacy of vertebroplasty for painful osteoporotic compression fractures remains uncertain. Two meta-analysis studies, which included the 2 sham-controlled trials, have demonstrated mixed results. The 2 studies had methodologic issues, including the choice of sham procedure and the potential of the sham procedure to have a therapeutic effect by reducing pain. Questions have also been raised about the low percentage of patients screened who participated in the trial, the volume of polymethylmethacrylate injected, and the inclusion of patients with chronic pain. One network meta-analysis found that relative to conservative treatment, vertebroplasty provided short-term and long-term improvements to pain relief and disability scores. Other meta-analyses had numerous limitations due to the heterogeneity of included studies or not specifying the timeframe for osteoporotic vertebral compression fractures. Overall, conclusions about the effect of vertebroplasty remain unclear. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with symptomatic osteoporotic vertebral fractures less than 6 weeks old who receive vertebroplasty, the evidence includes a randomized sham-controlled trial and nonblinded RCTs comparing vertebroplasty with conservative management. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. For acute fractures, conservative therapy consisting of rest, analgesics, and physical therapy is an option, and symptoms will resolve in a large percentage of patients with conservative treatment only. However, a sham-controlled randomized trial in patients who had severe pain of fewer than 6 weeks in duration found a significant benefit of vertebroplasty for the treatment of osteoporotic vertebral fracture at the thoracolumbar junction. Other RCTs without sham controls have reported that vertebroplasty is associated with significant improvements in pain and reductions in the duration of bed rest. Given the high morbidity associated with extended bed rest in older adults, this procedure is considered to have a significant health benefit. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with sacral insufficiency fractures who receive sacroplasty, the evidence includes 3 prospective cohort studies and a case series. Relevant outcomes are symptoms, functional outcomes, quality of life,

hospitalizations, medication use, and treatment-related morbidity. No RCTs have been reported. The prospective cohort studies and retrospective series of 243 patients have reported rapid and sustained decreases in pain following percutaneous sacroplasty. Additional literature has mostly reported immediate improvements following the procedure. However, due to the small size of the evidence base, the harms associated with sacroplasty have not been adequately studied. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteoporotic vertebral compression fracture who receive balloon kyphoplasty or mechanical vertebral augmentation, the evidence includes an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review, RCTs, and meta-analyses. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. The AHRQ review concluded that vertebroplasty was probably more effective at reducing pain and improving function in patients greater than 65 years of age, but benefits were small. Kyphoplasty was found to be probably more effective than usual care for pain and function in older patients with vertebral compression fracture at up to 1 month, and may be more effective at greater than 1 month to 1 year or more, but has not been compared against sham therapy. A meta-analysis and moderately-sized unblinded RCT have compared kyphoplasty with conservative care and found short-term benefits in pain and other outcomes. One systematic review of RCTs found no significant difference in subsequent fracture between vertebroplasty and conservative treatment, and another systematic review of prospective and retrospective studies reported improved mortality with either vertebroplasty or balloon kyphoplasty compared with conservative treatment. A network meta-analysis found that relative to conservative treatment, kyphoplasty provided short-term and long-term improvements to pain and disability scores. Other RCTs, summarized in a meta-analysis, have reported similar outcomes for kyphoplasty and vertebroplasty. A systematic review that compared mechanical vertebral augmentation (Kiva or SpineJack) with kyphoplasty have reported similar outcomes for both procedures. A major limitation of the available RCTs is the lack of a sham procedure. Due to the possible sham effect observed in the recent trials of vertebroplasty, the validity of the results from non-sham-controlled trials is unclear. Therefore, whether these improvements represent a true treatment effect is uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteolytic vertebral compression fracture who receive balloon kyphoplasty or mechanical vertebral augmentation, the evidence includes RCTs, case series, and systematic reviews of these studies. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. Two RCTs have compared balloon kyphoplasty with conservative management, and another has compared Kiva with balloon kyphoplasty. Results of these trials, along with case series, would suggest a reduction in pain, disability, and analgesic use in patients with cancer-related compression fractures. However, because the results of the comparative studies of vertebroplasty have suggested possible placebo or natural history effects, the evidence that these studies provide is insufficient to warrant conclusions about the effect of kyphoplasty on health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteoporotic or osteolytic vertebral compression fracture who receive radiofrequency kyphoplasty, the evidence includes a systematic review and an RCT. Relevant outcomes include symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related morbidity. The only RCT (N=80) identified showed similar results between radiofrequency kyphoplasty and balloon kyphoplasty. The systematic review suggested that radiofrequency kyphoplasty is superior to balloon kyphoplasty in pain relief, but the review itself was limited by the inclusion of a small number of studies as well as possible bias. Corroboration of these results in a larger number of patients would be needed to determine with greater certainty whether radiofrequency kyphoplasty provides outcomes similar to balloon kyphoplasty. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

# Professional Statements and Societal Positions Guidelines

Not Applicable

## Diagnosis Codes

### Diagnosis codes for 22510, 22511, 22512

C41.2	C79.51	C79.52	C90.00	C90.01	C90.02	D18.09
D47.Z9	M48.50XA	M48.50XD	M48.50XG	M48.50XS	M48.51	M48.51XA
M48.51XD	M48.51XG	M48.51XS	M48.52	M48.52XA	M48.52XD	M48.52XG
M48.52XS	M48.53	M48.53XA	M48.53XD	M48.53XG	M48.53XS	M48.54
M48.54XA	M48.54XD	M48.54XG	M48.54XS	M48.55	M48.55XA	M48.55XD
M48.55XG	M48.55XS	M48.56	M48.56XA	M48.56XD	M48.56XG	M48.56XS
M48.57	M48.57XA	M48.57XD	M48.57XG	M48.57XS	M48.58	M48.58XA
M48.58XD	M48.58XG	M48.58XS	M80.08XA	M80.08XD	M80.08XG	M80.08XK
M80.08XP	M80.08XS	M84.48XA	M84.48XD	M84.48XG	M84.48XK	M84.48XP
M84.48XS	M84.58XA	M84.58XD	M84.58XG	M84.58XK	M84.58XP	M84.58XS
M84.68XA	M84.68XD	M84.68XG	M84.68XK	M84.68XP	M84.68XS	

### Diagnosis codes for 22513, 22514, 22515

C41.2	C79.51	C79.52	C90.00	C90.01	C90.02	D18.09
D47.Z9	M48.50XA	M48.50XD	M48.50XG	M48.50XS	M48.51XA	M48.51XD
M48.51XG	M48.51XS	M48.52XA	M48.52XD	M48.52XG	M48.52XS	M48.53XA
M48.53XD	M48.53XG	M48.53XS	M48.54XA	M48.54XD	M48.54XG	M48.54XS
M48.55XA	M48.55XD	M48.55XG	M48.55XS	M48.56XA	M48.56XD	M48.56XG
M48.56XS	M48.57XA	M48.57XD	M48.57XG	M48.57XS	M48.58XA	M48.58XD

M48.58XG	M48.58XS	M54.6	M80.08XA	M80.08XD	M80.08XG	M80.08XK
M80.08XP	M80.08XS	M84.48XA	M84.48XD	M84.48XG	M84.48XK	M84.48XP
M84.48XS	M84.58XA	M84.58XD	M84.58XG	M84.58XK	M84.58XP	M84.58XS
M84.68XA	M84.68XD	M84.68XG	M84.68XK	M84.68XP	M84.68XS	

## References

1. Gotis-Graham I, McGuigan L, Diamond T, et al. Sacral insufficiency fractures in the elderly. *J Bone Joint Surg Br.* Nov 1994; 76(6): 882-6. PMID 7983111
2. Lin J, Lachmann E, Nagler W. Sacral insufficiency fractures: a report of two cases and a review of the literature. *J Womens Health Gend Based Med.* Sep 2001; 10(7): 699-705. PMID 11571100
3. Bae H, Hatten HP, Linovitz R, et al. A prospective randomized FDA-IDE trial comparing Cortoss with PMMA for vertebroplasty: a comparative effectiveness research study with 24-month follow-up. *Spine (Phila Pa 1976).* Apr 01 2012; 37(7): 544-50. PMID 21738093
4. Dehdashti AR, Martin JB, Jean B, et al. PMMA cementoplasty in symptomatic metastatic lesions of the S1 vertebral body. *Cardiovasc Intervent Radiol.* 2000; 23(3): 235-7. PMID 10821903
5. Marcy PY, Palussière J, Descamps B, et al. Percutaneous cementoplasty for pelvic bone metastasis. *Support Care Cancer.* Nov 2000; 8(6): 500-3. PMID 11094996
6. Aretxabala I, Fraiz E, Pérez-Ruiz F, et al. Sacral insufficiency fractures. High association with pubic rami fractures. *Clin Rheumatol.* 2000; 19(5): 399-401. PMID 11055834
7. Leroux JL, Denat B, Thomas E, et al. Sacral insufficiency fractures presenting as acute low-back pain. Biomechanical aspects. *Spine (Phila Pa 1976).* Dec 1993; 18(16): 2502-6. PMID 8303454
8. Newhouse KE, el-Khoury GY, Buckwalter JA. Occult sacral fractures in osteopenic patients. *J Bone Joint Surg Am.* Dec 1992; 74(10): 1472-7. PMID 1364816
9. Jarvik JG, Deyo RA. Cementing the evidence: time for a randomized trial of vertebroplasty. *AJNR Am J Neuroradiol.* Sep 2000; 21(8): 1373-4. PMID 11003266
10. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. *Ann Intern Med.* Mar 19 2002; 136(6): 471-6. PMID 11900500
11. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med.* May 24 2001; 344(21): 1594-602. PMID 11372012
12. Vase L, Riley JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. *Pain.* Oct 2002; 99(3): 443-452. PMID 12406519
13. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med.* Aug 06 2009; 361(6): 557-68. PMID 19657121
14. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med.* Aug 06 2009; 361(6): 569-79. PMID 19657122
15. Stratford PW, Binkley J, Solomon P, et al. Defining the minimum level of detectable change for the Roland-Morris questionnaire. *Phys Ther.* Apr 1996; 76(4): 359-65; discussion 366-8. PMID 8606899
16. Katz J, Melzack R. Measurement of pain. *Surg Clin North Am.* Apr 1999; 79(2): 231-52. PMID 10352653
17. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis. *TEC Assessments.* 2010;Volume 25:Tab 9.
18. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis. *TEC Assessments.* 2009;Volume 24:Tab 7.

19. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. TEC Assessments. 2008;Volume 23:Tab 5.
20. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. TEC Assessments. 2005;Volume 20:Tab 7.
21. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy. TEC Assessments. 2004;Volume 19:Tab 12.
22. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Percutaneous Vertebroplasty. TEC Assessments. 2000;Volume 15:Tab 21.
23. Barr JD, Jensen ME, Hirsch JA, et al. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS). *J Vasc Interv Radiol*. Feb 2014; 25(2): 171-81. PMID 24325929
24. Buchbinder R, Johnston RV, Rischin KJ, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. *Cochrane Database Syst Rev*. Apr 04 2018; 4(4): CD006349. PMID 29618171
25. Staples MP, Kallmes DF, Comstock BA, et al. Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. *BMJ*. Jul 12 2011; 343: d3952. PMID 21750078
26. Xie L, Zhao ZG, Zhang SJ, et al. Percutaneous vertebroplasty versus conservative treatment for osteoporotic vertebral compression fractures: An updated meta-analysis of prospective randomized controlled trials. *Int J Surg*. Nov 2017; 47: 25-32. PMID 28939236
27. Hinde K, Maingard J, Hirsch JA, et al. Mortality Outcomes of Vertebral Augmentation (Vertebroplasty and/or Balloon Kyphoplasty) for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis. *Radiology*. Apr 2020; 295(1): 96-103. PMID 32068503
28. Zhang L, Zhai P. A Comparison of Percutaneous Vertebroplasty Versus Conservative Treatment in Terms of Treatment Effect for Osteoporotic Vertebral Compression Fractures: A Meta-Analysis. *Surg Innov*. Feb 2020; 27(1): 19-25. PMID 31423902
29. Chang M, Zhang C, Shi J, et al. Comparison Between 7 Osteoporotic Vertebral Compression Fractures Treatments: Systematic Review and Network Meta-analysis. *World Neurosurg*. Jan 2021; 145: 462-470.e1. PMID 32891841
30. Liu Y, Liu J, Suvithayasiri S, et al. Comparative Efficacy of Surgical Interventions for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Network Meta-analysis. *Neurospine*. Dec 2023; 20(4): 1142-1158. PMID 38171285
31. Kroon F, Staples M, Ebeling PR, et al. Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures. *J Bone Miner Res*. Jun 2014; 29(6): 1346-55. PMID 24967454
32. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. *Spine (Phila Pa 1976)*. Jan 01 2008; 33(1): 90-4. PMID 18165753
33. Comstock BA, Sitlani CM, Jarvik JG, et al. Investigational vertebroplasty safety and efficacy trial (INVEST): patient-reported outcomes through 1 year. *Radiology*. Oct 2013; 269(1): 224-31. PMID 23696683
34. Firanesco CE, de Vries J, Lodder P, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. *BMJ*. May 09 2018; 361: k1551. PMID 29743284
35. Chen D, An ZQ, Song S, et al. Percutaneous vertebroplasty compared with conservative treatment in patients with chronic painful osteoporotic spinal fractures. *J Clin Neurosci*. Mar 2014; 21(3): 473-7. PMID 24315046

36. Farrokhi MR, Alibai E, Maghami Z. Randomized controlled trial of percutaneous vertebroplasty versus optimal medical management for the relief of pain and disability in acute osteoporotic vertebral compression fractures. *J Neurosurg Spine*. May 2011; 14(5): 561-9. PMID 21375382
37. Edidin AA, Ong KL, Lau E, et al. Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. *J Bone Miner Res*. Jul 2011; 26(7): 1617-26. PMID 21308780
38. Edidin AA, Ong KL, Lau E, et al. Morbidity and Mortality After Vertebral Fractures: Comparison of Vertebral Augmentation and Nonoperative Management in the Medicare Population. *Spine (Phila Pa 1976)*. Aug 01 2015; 40(15): 1228-41. PMID 26020845
39. Lin JH, Chien LN, Tsai WL, et al. Early vertebroplasty associated with a lower risk of mortality and respiratory failure in aged patients with painful vertebral compression fractures: a population-based cohort study in Taiwan. *Spine J*. Sep 2017; 17(9): 1310-1318. PMID 28483705
40. Clark W, Bird P, Gonski P, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. Oct 01 2016; 388(10052): 1408-1416. PMID 27544377
41. Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. *Lancet*. Sep 25 2010; 376(9746): 1085-92. PMID 20701962
42. Yi X, Lu H, Tian F, et al. Recompression in new levels after percutaneous vertebroplasty and kyphoplasty compared with conservative treatment. *Arch Orthop Trauma Surg*. Jan 2014; 134(1): 21-30. PMID 24287674
43. Leali PT, Solla F, Maestretti G, et al. Safety and efficacy of vertebroplasty in the treatment of osteoporotic vertebral compression fractures: a prospective multicenter international randomized controlled study. *Clin Cases Miner Bone Metab*. 2016; 13(3): 234-236. PMID 28228788
44. Yang EZ, Xu JG, Huang GZ, et al. Percutaneous Vertebroplasty Versus Conservative Treatment in Aged Patients With Acute Osteoporotic Vertebral Compression Fractures: A Prospective Randomized Controlled Clinical Study. *Spine (Phila Pa 1976)*. Apr 2016; 41(8): 653-60. PMID 26630417
45. Lourie H. Spontaneous osteoporotic fracture of the sacrum. An unrecognized syndrome of the elderly. *JAMA*. Aug 13 1982; 248(6): 715-7. PMID 7097924
46. Frey ME, Depalma MJ, Cifu DX, et al. Percutaneous sacroplasty for osteoporotic sacral insufficiency fractures: a prospective, multicenter, observational pilot study. *Spine J*. 2008; 8(2): 367-73. PMID 17981097
47. Kortman K, Ortiz O, Miller T, et al. Multicenter study to assess the efficacy and safety of sacroplasty in patients with osteoporotic sacral insufficiency fractures or pathologic sacral lesions. *J Neurointerv Surg*. Sep 01 2013; 5(5): 461-6. PMID 22684691
48. Frey ME, Warner C, Thomas SM, et al. Sacroplasty: A Ten-Year Analysis of Prospective Patients Treated with Percutaneous Sacroplasty: Literature Review and Technical Considerations. *Pain Physician*. Nov 2017; 20(7): E1063-E1072. PMID 29149151
49. Beall DP, Shonnard NH, Shonnard MC, et al. An Interim Analysis of the First 102 Patients Treated in the Prospective Vertebral Augmentation Sacroplasty Fracture Registry. *J Vasc Interv Radiol*. Sep 2023; 34(9): 1477-1484. PMID 37207812
50. Sarigul B, Ogrenci A, Yilmaz M, et al. Sacral insufficiency fracture: a single-center experience of 185 patients with a minimum 5-year follow-up. *Eur Spine J*. Apr 2024; 33(4): 1511-1517. PMID 37955749
51. Dougherty RW, McDonald JS, Cho YW, et al. Percutaneous sacroplasty using CT guidance for pain palliation in sacral insufficiency fractures. *J Neurointerv Surg*. Jan 2014; 6(1): 57-60. PMID 23345629
52. Zaman FM, Frey M, Slipman CW. Sacral stress fractures. *Curr Sports Med Rep*. Feb 2006; 5(1): 37-43. PMID 16483515
53. Denis F, Davis S, Comfort T. Sacral fractures: an important problem. Retrospective analysis of 236 cases. *Clin Orthop Relat Res*. Feb 1988; 227: 67-81. PMID 3338224
54. Chou R, Fu R, Dana T, et al. Interventional treatments for acute and chronic pain: systematic review [Internet]. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2021 Sep. Report No.: 21-EHC030



55. Zhao S, Xu CY, Zhu AR, et al. Comparison of the efficacy and safety of 3 treatments for patients with osteoporotic vertebral compression fractures: A network meta-analysis. *Medicine (Baltimore)*. Jun 2017; 96(26): e7328. PMID 28658144
56. Sun HB, Jing XS, Tang H, et al. Clinical and radiological subsequent fractures after vertebral augmentation for treating osteoporotic vertebral compression fractures: a meta-analysis. *Eur Spine J*. Oct 2020; 29(10): 2576-2590. PMID 32776263
57. Halvachizadeh S, Stalder AL, Bellut D, et al. Systematic Review and Meta-Analysis of 3 Treatment Arms for Vertebral Compression Fractures: A Comparison of Improvement in Pain, Adjacent-Level Fractures, and Quality of Life Between Vertebroplasty, Kyphoplasty, and Nonoperative Management. *JBS Rev*. Oct 25 2021; 9(10). PMID 34695056
58. Ong KL, Beall DP, Frohbergh M, et al. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty "sham" trials?. *Osteoporos Int*. Feb 2018; 29(2): 375-383. PMID 29063215
59. Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. *Lancet*. Mar 21 2009; 373(9668): 1016-24. PMID 19246088
60. Boonen S, Van Meirhaeghe J, Bastian L, et al. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. *J Bone Miner Res*. Jul 2011; 26(7): 1627-37. PMID 21337428
61. Van Meirhaeghe J, Bastian L, Boonen S, et al. A randomized trial of balloon kyphoplasty and nonsurgical management for treating acute vertebral compression fractures: vertebral body kyphosis correction and surgical parameters. *Spine (Phila Pa 1976)*. May 20 2013; 38(12): 971-83. PMID 23446769
62. Macciachera M, McDonnell JM, Amir A, et al. Mechanical Vertebral Body Augmentation Versus Conventional Balloon Kyphoplasty for Osteoporotic Thoracolumbar Compression Fractures: A Systematic Review and Meta-Analysis of Outcomes. *Global Spine J*. Mar 2025; 15(2): 1356-1366. PMID 38889443
63. Tutton SM, Pflugmacher R, Davidian M, et al. KAST Study: The Kiva System As a Vertebral Augmentation Treatment-A Safety and Effectiveness Trial: A Randomized, Noninferiority Trial Comparing the Kiva System With Balloon Kyphoplasty in Treatment of Osteoporotic Vertebral Compression Fractures. *Spine (Phila Pa 1976)*. Jun 15 2015; 40(12): 865-75. PMID 25822543
64. Korolessis P, Vardakastanis K, Repantis T, et al. Balloon kyphoplasty versus KIVA vertebral augmentation--comparison of 2 techniques for osteoporotic vertebral body fractures: a prospective randomized study. *Spine (Phila Pa 1976)*. Feb 15 2013; 38(4): 292-9. PMID 23407406
65. Noriega D, Marcia S, Theumann N, et al. A prospective, international, randomized, noninferiority study comparing an implantable titanium vertebral augmentation device versus balloon kyphoplasty in the reduction of vertebral compression fractures (SAKOS study). *Spine J*. Nov 2019; 19(11): 1782-1795. PMID 31325625
66. Pron G, Holubowich C, Kaulback K. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. *Ont Health Technol Assess Ser*. 2016; 16(11): 1-202. PMID 27298655
67. Mattie R, Brar N, Tram JT, et al. Vertebral Augmentation of Cancer-Related Spinal Compression Fractures: A Systematic Review and Meta-Analysis. *Spine (Phila Pa 1976)*. Dec 15 2021; 46(24): 1729-1737. PMID 33958537
68. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. *Lancet Oncol*. Mar 2011; 12(3): 225-35. PMID 21333599
69. Korolessis P, Vardakastanis K, Vitsas V, et al. Is Kiva implant advantageous to balloon kyphoplasty in treating osteolytic metastasis to the spine? Comparison of 2 percutaneous minimal invasive spine techniques: a prospective randomized controlled short-term study. *Spine (Phila Pa 1976)*. Feb 15 2014; 39(4): E231-9. PMID 24253785
70. Feng L, Shen JM, Feng C, et al. Comparison of radiofrequency kyphoplasty (RFK) and balloon kyphoplasty (BKP) in the treatment of vertebral compression fractures: A meta-analysis. *Medicine (Baltimore)*. Jun

- 2017; 96(25): e7150. PMID 28640091
71. Petersen A, Hartwig E, Koch EM, et al. Clinical comparison of postoperative results of balloon kyphoplasty (BKP) versus radiofrequency-targeted vertebral augmentation (RF-TVA): a prospective clinical study. *Eur J Orthop Surg Traumatol*. Jan 2016; 26(1): 67-75. PMID 26482590
  72. Baerlocher MO, Saad WE, Dariushnia S, et al. Quality improvement guidelines for percutaneous vertebroplasty. *J Vasc Interv Radiol*. Feb 2014; 25(2): 165-70. PMID 24238815
  73. ACR-ASNR-ASSR-SIR-SNIS Practice Parameter for the Performance of Vertebral Augmentation. Available at [https://www.sirweb.org/practice-resources/clinical-practice/guidelines-and-statements/neuro-and-spine/collaboration\\_endorsements/acr\\_sir-vertebral-augment/](https://www.sirweb.org/practice-resources/clinical-practice/guidelines-and-statements/neuro-and-spine/collaboration_endorsements/acr_sir-vertebral-augment/). Accessed February 18, 2025.
  74. American College of Radiology. Management of vertebral compression fractures. <https://acsearch.acr.org/docs/70545/Narrative/>. Published 2022. Accessed February 18, 2025.
  75. McGuire R. AAOS Clinical Practice Guideline: the Treatment of Symptomatic Osteoporotic Spinal Compression Fractures. *J Am Acad Orthop Surg*. Mar 2011; 19(3): 183-4. PMID 21368100
  76. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty [IPG12]. 2003; <https://www.nice.org.uk/guidance/ipg12>. Accessed February 15, 2025.
  77. National Institute for Health and Care Excellence (NICE). Spinal metastases and metastatic spinal cord compression [NG234]. 2023; <https://www.nice.org.uk/guidance/ng234>. Accessed February 17, 2025.
  78. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures [TA279]. 2013; <https://www.nice.org.uk/guidance/ta279>. Accessed February 16, 2025.
  79. Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain. *J Pain Res*. 2021; 14: 2139-2164. PMID 34295184

## ND Committee Review

Internal Medical Policy Committee 09-04-2025 *Effective November 3, 2025*

- *Adopted* policy

## Disclaimer

*Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.*